Products You May Like
TORONTO, Could 24, 2021 (GLOBE NEWSWIRE) — Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical system firm centered on the design and growth of surgical applied sciences for robotic single entry surgical procedure, right this moment introduced the addition of Deepak Basra as Vice President, Technique and Enterprise Growth to the management crew. On this newly created function, Mr. Basra will oversee Titan’s company growth and strategic planning.
“We’re thrilled to welcome Deepak to Titan. His wealth of information and expertise in enterprise growth and strategic partnerships can be instrumental in rising Titan,” mentioned David McNally, President and Chief Government Officer of Titan. “We stay up for Deepak’s contributions as we execute on our imaginative and prescient of advancing our Enos™ robotic single entry surgical procedure system.”
Mr. Basra joins Titan with over 20 years’ expertise in international enterprise growth and mergers and acquisitions (M&A). Most lately, he served as Senior Vice President with Cortland Advisers, LLC, a world M&A advisory agency. His company expertise consists of serving as Board Director and Vice President, Technique and Enterprise growth for Transdermal Supply Options Company (TDSC). Previous to TDSC, he was Head of Enterprise Growth and Licensing for Covidien’s vascular therapies division. He additionally served as Senior Vice President, Technique and Enterprise Growth at Smith & Nephew previous to Covidien. Earlier, Mr. Basra held varied enterprise growth, M&A and alliance administration roles of accelerating accountability at Cable & Wi-fi, British Telecommunications PLC, and at Phillips within the telecommunications division. Mr. Basra holds a Bachelor of Science from Edinburgh College, a Submit-Graduate Diploma in Worldwide Advertising from Buckinghamshire Faculty, UK, and a Grasp of Enterprise Administration from Henley Administration Faculty, UK.
About Titan Medical Inc.
Titan Medical Inc. is a medical system firm headquartered in Toronto, Ontario and with R&D services in Chapel Hill, North Carolina, is concentrated on enhancing robotic assisted surgical procedure utilizing revolutionary know-how by way of a single entry level. The Enos™ robotic single entry surgical system is being developed with an ergonomic focus to offer a surgical expertise that imitates real-life actions that surgeons demand, and consists of multi-articulating devices designed to permit surgeons an elevated vary of movement in a confined area, with dexterity and the power to exert the forces needed to finish frequent surgical duties. With the Enos system, Titan intends to initially pursue gynecologic surgical indications. Sure of Titan’s robotic assisted surgical applied sciences and associated mental property have been licensed to Medtronic plc, whereas retaining world-wide rights to commercialize the applied sciences to be used with the Enos system.
Enos™ is a trademark of Titan Medical Inc.
For extra data, go to www.titanmedicalinc.com.
Ahead-Trying Statements
This information launch incorporates “forward-looking statements” inside the which means of relevant Canadian and U.S. securities legal guidelines, which mirror the present expectations of administration of the Firm’s future progress, outcomes of operations, efficiency, and enterprise prospects and alternatives. Wherever attainable, phrases equivalent to “could”, “would”, “may”, “will”, “anticipate”, “consider”, “plan”, “anticipate”, “intend”, “estimate”, “potential for” and comparable expressions have been used to determine these forward-looking statements, together with, with out limitation, references to: the Firm’s concentrate on the design and growth of surgical applied sciences for robotic single entry surgical procedure, the Enos system is being developed with twin 3D and 2D high-definition imaginative and prescient techniques, multi-articulating devices and an ergonomic surgeon workstation, and that Titan intends to initially pursue gynecologic surgical indications. These statements mirror administration’s present beliefs, and are based mostly on data at the moment out there to administration. Ahead-looking statements contain vital dangers, uncertainties and assumptions. Many elements may trigger the Firm’s precise outcomes, efficiency or achievements to be materially totally different from any future outcomes, efficiency or achievements which may be expressed or implied by such forward-looking statements, together with, with out limitation, these listed within the “Threat Components” part of the Firm’s Annual Info Kind and Kind 40-F for the fiscal yr ended December 31, 2020 (which can be considered at www.sedar.com and at www.sec.gov). Ought to a number of of those dangers or uncertainties materialize, or ought to assumptions underlying the forward-looking statements show incorrect, precise outcomes, efficiency, or achievements could range materially from these expressed or implied by the forward-looking statements contained on this information launch. These elements must be thought of fastidiously, and potential traders shouldn’t place undue reliance on the forward-looking statements. Though the forward-looking statements contained within the information launch are based mostly upon what administration at the moment believes to be cheap assumptions, the Firm can not guarantee potential traders that precise outcomes, efficiency or achievements can be according to these forward-looking statements. Besides as required by legislation, the Firm expressly disclaims any intention or obligation to replace or revise any forward-looking statements whether or not on account of new data, future occasions or in any other case.
Contact
Kristen Galfetti
Vice President, Investor Relations
& Company Communications
+1-781-869-2553
investors@titanmedicalinc.com